Intervention

SHR-1316

ClinicalTrials.gov intervention label

Clinical trials10

Recruiting3

Common conditions17

Lead sponsors shown5

Clinical trials

10 shown

A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With NSCLCNCT06754930 · 2025-02-18

Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant TherapyNCT05582499 · 2022-11-01

Reverse Triple Negative Immune Resistant Breast CancerNCT05076682 · 2022-06-30

A Phase II Clinical Study of SHR-7787 Injection Combined With SHR-1316 Injection in Patients With LS-SCLCNCT07798947 · 2026-09-01

NOT_YET_RECRUITING

Study of Multi-mode Thermal Therapy Combined With Immunotherapy In Patients With HER2-negative Breast Cancer With Liver MetastasesNCT07466927 · 2026-03-15

NOT_YET_RECRUITING

Immune Therapy in HR-positive/HER2-negative Metastatic Breast Cancer(ENIGMA)-BCTOP-L-M02NCT05205200 · 2022-06-06

A Trial of SHR-1316 Maintenance Therapy for Limited Stage Small Cell Lung CancerNCT04647357 · 2020-11-27

A Study of Fluzoparib (SHR-3162) and Temozolomide With or Without SHR-1316 in Treating Patients With Replapsed Small Cell Lung CancerNCT04400188 · 2020-06-11

A Phase II Study of Triple-negative Breast Cancer Brain Metastases.NCT04303988 · 2020-03-30

Study of Carboplatin Plus Etoposide With or Without SHR-1316 in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)NCT03711305 · 2018-12-30

Common conditions

Breast Cancer3 HER2-negative Breast Cancer2 Breast Neoplasm1 Breast Tumors1 Early-stage Breast Cancer1 Extensive-stage Small Cell Lung Cancer1 HER2-positive Breast Cancer1 Hormone Receptor Negative Tumor1 Hormone Receptor Positive Tumor1 Limited-stage Small Cell Lung Cancer, LS-SCLC1 Limited-stage Small-cell Lung Cancer1 Locally Advanced Breast Cancer1 Metastatic Cancer1 Non-small Cell Lung Cancer (NSCLC)1 Small Cell Lung Cancer1 Triple-negative Breast Cancer1 Triple-Negative Breast Cancer (TNBC)1

Leading sponsors

Fudan University5 Jiangsu HengRui Medicine Co., Ltd.2 Shanghai Hengrui Pharmaceutical Co., Ltd.1 Suzhou Suncadia Biopharmaceuticals Co., Ltd.1 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology1

Trial status mix

UNKNOWN4

RECRUITING3

NOT_YET_RECRUITING2

COMPLETED1

Phase mix

PHASE29

PHASE12

PHASE31

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.